secwatch.observer — SEC 8-K summary
======================================

Issuer:     Aptevo Therapeutics Inc. (APVO)
CIK:        0001671584
Form:       8-K
Filed at:   2025-02-14T23:59:59+00:00
Accession:  0000950170-25-020465
Event type: other_material
Sentiment:  positive
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Aptevo reports 100% remission in Cohort 1 of RAINIER AML trial; 59% stable disease rate in ALG.APV-527 trial
--------------------------------------------------------------------------------

- Mipletamig RAINIER Cohort 1: 100% of patients achieved remission within 30 days, including one MRD-negative status.
- ALG.APV-527 Phase 1: 59% (10/17 evaluable) stable disease rate; breast cancer patient stable >12 months.
- Company expects multiple data readouts in 2025 and will present at ASH in Q4 2025.
- No specific financial results for FY 2024 are disclosed in the provided exhibit text.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1671584/000095017025020465/0000950170-25-020465-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1671584/000095017025020465/apvo-20250214.htm
  HTML page:      https://secwatch.observer/filing/0000950170-25-020465

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer